Cambridge Cognition Holdings Plc is a neuroscience technology company focused on developing and globally marketing sophisticated cognitive testing solutions for use in clinical settings. The firm operates internationally, serving clients in the United States, United Kingdom, and European Union, among other regions. Its extensive product portfolio includes CANTAB Recruit, an online platform designed to help pharmaceutical and biotechnology companies efficiently identify and onboard eligible participants for clinical trials, particularly in high-need therapeutic areas such as Alzheimer's disease. For broader pharmaceutical research, CANTAB Connect offers digital cognitive assessment tools applicable across all clinical trial phases (I-IV) and various medical fields. Additionally, the Cognition Kit is a digital health platform that utilizes wearable and smartphone applications to collect data, aiming to boost patient involvement, validate treatment efficacy, and deepen understanding of diseases and individual responses to medication. Other specialized offerings include CANTAB Connect Research, advanced software providing precise digital metrics for cognitive function in brain research; CANTAB Mobile, a touchscreen memory test frequently used in clinical studies pertaining to Alzheimer's disease; and CANTAB BrainHealth, an online digital assessment tool for monitoring mental well-being and cognitive performance in professional environments. The company also provides CANTAB Insight, a medical device for evaluating an individual's cognitive health, and NeuroVocalix, a secure platform enabling automated administration and scoring of validated verbal cognitive assessments. Beyond its technological products, Cambridge Cognition furnishes a suite of expert consultancy and operational management services tailored to enhance clinical trials and cognitive research. These services encompass neuroscience and technical advice, study design, data analysis, comprehensive study and data management, and the provision of insightful reports and interpretations. Cambridge Cognition Holdings Plc was established in 2012 and is headquartered in Cambridge, United Kingdom.
The current price of COG.LSE is GBX27.00 GBX — it has decreased by -3.57% in the past 24 hours. Watch Cambridge Cognition stock price performance more closely on the chart.
What is Cambridge Cognition stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on London Exchange exchange Cambridge Cognition stocks are traded under the ticker COG.LSE.
Is Cambridge Cognition stock price growing?▼
COG.LSE stock has fallen by -2.8% compared to the previous week, the month change is a -1.89% fall, over the last year Cambridge Cognition has showed a -18.31% decrease.
What is Cambridge Cognition market cap?▼
Today Cambridge Cognition has the market capitalization of 12.59M
When is the next Cambridge Cognition earnings date?▼
Cambridge Cognition is going to release the next earnings report on May 5, 2027.
What were Cambridge Cognition earnings last quarter?▼
COG.LSE earnings for the last quarter are -1.58 GBX per share, whereas the estimation was N/A GBX resulting in a N/A surprise. The estimated earnings for the next quarter are N/A GBX per share.
What is Cambridge Cognition revenue for the last year?▼
Cambridge Cognition revenue for the last year amounts to 940M GBX.
What is Cambridge Cognition net income for the last year?▼
COG.LSE net income for the last year is -167.5M GBX.
How many employees does Cambridge Cognition have?▼
As of November 2, 2026, the company has 74 employees.
In which sector is Cambridge Cognition located?▼
Cambridge Cognition operates in the Health & Wellness sector.
When did Cambridge Cognition complete a stock split?▼
Cambridge Cognition has not had any recent stock splits.
Where is Cambridge Cognition headquartered?▼
Cambridge Cognition is headquartered in Cambridge, United Kingdom.